Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational program upon INDβ¦





